alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Gloria Sleeper et al. *v.*Audrey S. Baines et al.

*Richard J. Joseph,*for the appellee (defendant Vanna B. McMullin).

*F. Mac Buckley,*for the appellants (plaintiffs).

Argued March 4

decided March 5, 1969

The motion by the defendant Yanna B. McMullin to dismiss the appeal from the Superior Court in Fairfield County at Stamford is granted.
§ 520.1664 Oxytetracycline and carbomycin. ( a ) *Specifications.* ( 1 ) Oxytetracycline: The antibiotic substance produced by growth of *Streptomyces rimosus* or the same antibiotic substance produced by any other means.
( 2 ) Carbomycin: The antibiotic substance produced by growth of *Streptomyces halstedii* or the same antibiotic substance produced by any other means.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Special considerations.* The quantities of oxytetracycline in paragraph (e) of this section refer to the activity of oxytetracycline hydrochloride and the quantities of carbomycin listed refer to the activity of an appropriate standard.
( d ) *Related tolerances.* See §§ 556.110 and 556.500 of this chapter.
( e ) *Conditions of use.* It is used as oxytetracycline hydrochloride plus carbomycin base in drinking water of chickens as follows: ( 1 ) *Amount.* Administer 1.0 gram of oxytetracycline and 1.0 gram carbomycin per gallon for not more than 5 days.
( 2 ) *Indications for use.* As an aid in the prevention and treatment of complicated chronic respiratory disease (air-sac infection) caused by *Mycoplasma gallisepticum* and secondary bacterial organisms associated with chronic respiratory disease such as *E. coli.*
( 3 ) *Limitations.* Not for use in chickens producing eggs for human consumption. Withdraw 24 hours before slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 78 FR 28825, May 20, 2014; 81 FR 94989, Dec. 27, 2016. Redesignated at 88 FR 55563, Aug. 16, 2023]
I 

118TH CONGRESS 

2D SESSION H. R. 7480 

To amend section 102(a)(20) of the Housing and Community Development 

Act of 1974 to require the exclusion of service-connected disability compensation when determining whether a person is a person of low and 

moderate income, a person of low income, or a person of moderate 

income, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 29, 2024 

Ms. DE LA CRUZ (for herself, Mr. SHERMAN, Mr. LAWLER, Ms. WILD, Mrs. 

CHAVEZ-DEREMER, Mr. BARR, Mr. MOLINARO, Mr. D’ESPOSITO, Mr. 

WEBER of Texas, Mr. MOYLAN, Mr. CISCOMANI, Mr. YAKYM, Mr. 

CUELLAR, and Mr. CRENSHAW) introduced the following bill; which was 

referred to the Committee on Financial Services 

A BILL 

To amend section 102(a)(20) of the Housing and Community 

Development Act of 1974 to require the exclusion of 

service-connected disability compensation when determining whether a person is a person of low and moderate 

income, a person of low income, or a person of moderate 

income, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7480 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Disabled Veterans 

3 Housing Support Act’’. 

4 SEC. 2. SERVICE CONNECTED DISABILITY COMPENSATION. 

5 Section 102(a)(20) of the Housing and Community 

6 Development Act of 1974 (42 U.S.C. 5302(a)(20)) is 

7 amended by adding at the end the following: 

8 ‘‘(C) SERVICE-CONNECTED DISABILITY

9 COMPENSATION.—When determining whether a 

10 person is of a person of low and moderate in11 come, a person of low income, or a person of 

12 moderate income under this paragraph, a State, 

13 unit of general local government, or Indian 

14 tribe shall exclude any service-connected dis15 ability compensation received by such person 

16 from the Department of Veterans Affairs.’’. 

17 SEC. 3. REPORT. 

18 The Comptroller General of the United States shall, 

19 not later than 1 year after the date of the enactment of 

20 this Act, submit to the Congress a report that— 

21 (1) examines how service-connected disability 

22 compensation is treated for the purposes of deter23 mining eligibility for all programs administered by 

24 the Secretary of Housing and Urban Development 

25 and identifies any cases where service-connected disVerDate Sep 11 2014 01:01 Mar 04, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7480.IH H7480

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7480 IH

1 ability compensation is treated inconsistently across 

2 a program; and 

3 (2) with respect to each program administered 

4 by the Secretary of Housing and Urban Develop5 ment, provides legislative recommendations relating 

6 to how such program could better serve veteran pop7 ulations, and under-served communities. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     September 30, 2000 Financial Data Schedule for Healthcare Properties, L.P.
</LEGEND>
<CIK>                         0000814458
<NAME>                        Healthcare Properties, L.P.
<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>               DEC-31-2000
<PERIOD-START>                  JAN-01-2000
<PERIOD-END>                    SEP-30-2000
<EXCHANGE-RATE>                 1
<CASH>                          15,127,101
<SECURITIES>                    0
<RECEIVABLES>                   1,012,386
<ALLOWANCES>                    (368,669)
<INVENTORY>                     0
<CURRENT-ASSETS>                0
<PP&E>                          18,386,000
<DEPRECIATION>                  (7,119,919)
<TOTAL-ASSETS>                  27,164,994
<CURRENT-LIABILITIES>           0
<BONDS>                         0
<PREFERRED-MANDATORY>           0
<PREFERRED>                     0
<COMMON>                        0
<OTHER-SE>                      21,524,311
<TOTAL-LIABILITY-AND-EQUITY>    27,164,994
<SALES>                         0
<TOTAL-REVENUES>                7,555,334
<CGS>                           0
<TOTAL-COSTS>                   4,914,837
<OTHER-EXPENSES>                82,800
<LOSS-PROVISION>                0
<INTEREST-EXPENSE>              379,808
<INCOME-PRETAX>                 2,177,889
<INCOME-TAX>                    0
<INCOME-CONTINUING>             0
<DISCONTINUED>                  0
<EXTRAORDINARY>                 0
<CHANGES>                       0
<NET-INCOME>                    2,177,889
<EPS-BASIC>                     .51
<EPS-DILUTED>                   .51



</TABLE>
§ 26.20 Alert system. ( a ) The details of an alert system will be developed during the transitional period. The system will be maintained in place at all times. Elements to be considered in developing such a system are described in appendix E of this subpart.
( b ) Contact points will be agreed between both parties to permit authorities to be made aware with the appropriate speed in case of quality defect, recalls, counterfeiting, and other problems concerning quality, which could necessitate additional controls or suspension of the distribution of the product.
§ 522.1703 Pentobarbital. ( a ) *Specifications.* Each milliliter of solution contains 64.8 milligrams (mg) of sodium pentobarbital.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* The drug is administered intravenously “to effect”. For general surgical anesthesia, the usual dose is 11 to 13 mg per pound of body weight. For sedation, the usual dose is approximately 2 mg per pound of body weight. For relieving convulsive seizures caused by strychnine in dogs, the injection should be administered intravenously “to effect”. The drug may be administered intraperitoneally. When given intraperitoneally, it is administered at the same dosage level as for intravenous administration.
( 2 ) *Indications for use.* The drug is indicated for use as a general anesthetic in dogs and cats. Although it may be used as a general surgical anesthetic for horses, it is usually given at a lower dose to cause sedation and hypnosis and may be supplemented with a local anesthetic. It may also be used in dogs for the symptomatic treatment of strychnine poisoning.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16193, Mar. 25, 2014. Redesignated at 86 FR 61685, Nov. 8, 2021]
**Exhibit 23.2**

 

**INDEPENDENT AUDITORS’ CONSENT**

 

We consent to the incorporation by reference in Registration Statement Nos. 333-111978, 333-108617, 333-81208, 333-71954,333-70976, 333-60132, 333-43038, 333-40322 and 333-35876 on Form S-3 and Nos. 333-108619, 333-70982, 333-38964 and 333-35874 on Form S-8 of GlycoGenesys, Inc. of our report dated May 29, 2002, except for Note 6, as to which the date is December 18,2002, (which report expresses an unqualified opinion and includes an explanatory paragraph referring to SafeScience Newco, Ltd.’s ability to continue as a going concern) relating to the financial statements of SafeScience Newco, Ltd., as of andfor the period ended December 31, 2001 appearing in this Annual Report on Form 10-K of GlycoGenesys, Inc. for the year ended December 31, 2003. 

 

/s/    DELOITTE & TOUCHE LLP 

 

Boston, Massachusetts 

March 29, 2004
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1012 α-Amylase enzyme preparation from Bacillus stearothermophilus. ( a ) α-Amylase enzyme preparation is obtained from the culture filtrate that results from a pure culture fermentation of a nonpathogenic and nontoxicogenic strain of *Bacillus stearothermophilus.* Its characterizing enzyme activity is α-amylase (1,4 α-D glucan glucanohydrolase (E.C. 3.2.1.1)).
( b ) The ingredient meets the general and additional requirements for enzyme preparations in the “Food Chemicals Codex,” 3d ed. (1981), pp. 107-110, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the Office Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practices. The affirmation of this ingredient as GRAS as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme, as defined in § 170.3(o)(9) of this chapter, in the hydrolysis of edible starch to produce maltodextrins and nutritive carbohydrate sweeteners.
( 2 ) The ingredient is used at levels not to exceed current good manufacturing practices.
[60 FR 55789, Nov. 3, 1995, as amended at 78 FR 14666, Mar. 7, 2013]
Exhibit
15.1
  CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS
  We hereby
consent to the incorporation by reference in the Registration Statement (Form
S-8 No. 333-106591) of Deutsche Telekom AG of our reports dated February 27,
2009 with respect to the consolidated financial statements and the effectiveness
of internal control over financial reporting of the Company included in this
Annual Report (Form 20-F) for the year ended December 31, 2008.
  February
27, 2009
 
  Ernst
      & Young AG
                                      Wirtschaftsprüfungsgesellschaft
                                      Steuerberatungsgesellschaft
                                      Stuttgart/s/
      Prof. Dr. Wollmert
                                      (Prof.
      Dr. Wollmert)
                                      Wirtschaftsprüfer
                                    
                                    /s/ Forst
                                      (Forst)
                                      WirtschaftsprüferPricewaterhouseCoopers
                                      Aktiengesellschaft
                                      Wirtschaftsprüfungsgesellschaft
                                      Frankfurt
      am Main/s/
      Prof. Dr. Kämpfer
                                      (Prof.
      Dr. Kämpfer)
                                      Wirtschaftsprüfer
                                    
                                    /s/
      Menke
                                      (Menke)
                                      Wirtschaftsprüfer
§ 528.2010 Human lysosomal acid lipase recombinant deoxyribonucleic acid construct. ( a ) *Specifications.* A single copy of a human lysosomal acid lipase (hLAL) recombinant deoxyribonucleic acid (rDNA) gene construct located at the SYN LAL-C site in chromosome 6 in a specific, diploid line (SBC LAL-C) of hemizygous and homozygous domestic chickens (*Gallus gallus*), derived from the lineage progenitor XLL 109.
( b ) *Sponsor.* See No. 069334 in § 510.600 of this chapter.
( c ) *Conditions of use* — ( 1 ) *Intended use.* The gene construct directs the expression of that encoding gene such that recombinant, human lysosomal acid lipase (rhLAL) protein intended for the treatment of human disease is present in SBC LAL-C chicken egg whites.
( 2 ) *Limitations.* Food or feed from XLL 109 chickens is not permitted in the food or feed supply.
[81 FR 17608, Mar. 30, 2016]
§ 524.1484b Neomycin, isoflupredone, and tetracaine powder. ( a ) *Specifications.* Each 15-gram insufflator bottle contains 5 milligrams (mg) neomycin sulfate (equivalent to 3.5 mg neomycin base), 1 mg isoflupredone acetate, and 5 mg tetracaine hydrochloride in a powder base.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses, dogs, and cats* — ( 1 ) *Amount.* Apply to affected areas as a dusting powder.
( 2 ) *Indications for use.* For the treatment or as adjunctive therapy of certain ear and skin conditions caused by or associated with neomycin-susceptible organisms and/or allergy; as a superficial dressing applied to minor cuts, wounds, lacerations, abrasions, and for postsurgical application where reduction of pain and inflammatory response is deemed desirable; as a dusting powder following amputation of tails, claws, and dewclaws and following ear trimming, castrating, and such surgical procedures as ovariohysterectomies. For the treatment of acute otitis externa, acute moist dermatitis, and interdigital dermatitis in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978; 79 FR 10970, Feb. 27, 2014; 85 FR 45308, July 28, 2020]
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 96-6178

GARETH JEROME WILSON,

Plaintiff - Appellant,

versus

JANET RENO; UNITED STATES MARSHAL SERVICE;

CHRISTINE WHITMAN, Governor of New Jersey;

UNITED STATES PAROLE COMMISSION; JOHN HAHN,

Warden of Petersburg Federal Correctional

Institution,

Defendants - Appellees.

Appeal from the United States District Court for the Eastern

District of Virginia, at Alexandria. Albert V. Bryan, Jr., Senior

District Judge. (CA-95-1570-AM)

Submitted: April 9, 1996 Decided: May 30, 1996

Before MURNAGHAN and WILLIAMS, Circuit Judges, and PHILLIPS, Senior

Circuit Judge.

Affirmed by unpublished per curiam opinion.

Gareth Jerome Wilson, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Gareth Jerome Wilson filed a Petition for a Writ of Mandamus

in the Eastern District of Virginia seeking to compel Respondents

to dismiss a New Jersey indictment filed against him. The district

court denied his requested relief without prejudice to his right to

apply to the appropriate New Jersey court. Wilson appeals.

Mandamus is a drastic remedy to be used only in extraordinary

circumstances. Kerr v. United States Dist. Court, 426 U.S. 394, 402

(1976). "[C]ourts are extremely reluctant to grant a writ of mandamus." In re Ford Motor Co., 751 F.2d 274, 275 (8th Cir. 1984). In

seeking mandamus relief, a petitioner carries the heavy burden of

showing that he has no other adequate means to attain the relief

and that his right to such relief is clear and indisputable. In re

First Fed. Sav. & Loan Ass'n, 860 F.2d 135, 138 (4th Cir. 1988).

Because Appellant may seek the requested relief in the appropriate

New Jersey court, by habeas corpus or otherwise, we affirm.

We dispense with oral argument because the facts and legal

contentions are adequately presented in the materials before the

court and argument would not aid the decisional process.

AFFIRMED
11 TH COURT OF APPEALS

EASTLAND

, TEXAS

JUDGMENT

The State of Texas

, * From the 32nd District

Court of Mitchell County,

Trial Court No. 7363

.

Vs. No. 11

- 12

- 00315

- CR * May 30, 2014

John Berry Jackson

, * Opinion by Wright, C.J

. (Panel consists of: Wright, C.J.,

Willson , J. , and Bailey, J. )

This court has inspected the record in this cause and concludes that there is

no error in the order below. Therefore, in accordance with this court ’ s opinion,

the order of the trial court is in all things affirmed. The costs incurred by reason

of this appeal are taxed against the State of Texas.
#### § 582.60 Synthetic flavoring substances and adjuvants.

Synthetic flavoring substances and adjuvants that are generally recognized as safe for their intended use, within the meaning of section 409 of the act, are as follows:

Acetaldehyde (ethanal).

Acetoin (acetyl methylcarbinol).

Aconitic acid (equisetic acid, citridic acid, achilleic acid).

Anethole (parapropenyl anisole).

Benzaldehyde (benzoic aldehyde).

*N*-Butyric acid (butanoic acid).

*d*- or *l*-Carvone (carvol).

Cinnamaldehyde (cinnamic aldehyde).

Citral (2,6-dimethyloctadien-2,6-*al*-8, geranial, neral).

Decanal (*N*-decylaldhehyde, capraldehyde, capric aldehyde, caprinaldehyde, aldehyde *C*-10).

Diacetyl (2,3-butandeione). Ethyl acetate. Ethyl butyrate.

3-Methyl-3-phenyl glycidic acid ethyl ester (ethyl-methyl-phenyl-glycidate, so-called strawberry aldehyde, C-16 aldehyde).

Ethyl vanillin.

Eugenol.

Geraniol (3,7-dimethyl-2,6 and 3,6-octadien-1-*ol*).

Geranyl acetate (geraniol acetate).

Glycerol (glyceryl) tributyrate (tributyrin, butyrin).

Limonene (*d-, l-, and dl-*).

Linalool (linalol, 3,7-dimethyl-1,6-octadien-3-*ol*).

Linalyl acetate (bergamol).

*l*-Malic acid.

Methyl anthranilate (methyl-2-aminobenzoate).

Piperonal (3,4-methylenedioxy-benzaldehyde, heliotropin).

Vanillin.
#### William J. Verriker et al. *v.*Waterbury Redevelopment Agency

King, C. J., Alcorn, House, Thim and Ryan, Js.

Argued October 9

decided October 9, 1969

*John D. Mahoney,*with whom were *Robert 8. Kolesnik*and, on the brief, *Albert L. Finkelstein*and *James F. Meenan,*for the appellant (defendant).

*Ernest A. Inglis, Jr.,*with whom were *Max R. Traurig*and, on the brief, *Charles W. Page,*for the appellees (plaintiffs).

Per Curiam.

There is no error.
[No. 39854-7-I.

Division One.

November 3, 1997.]

#### *In the Matter of the Marriage of*Elaine Adairre Edwards, *Respondent,*and James Peter Edwards, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 92-3-01545-9, Richard Eadie, J., entered November 4, 1996. *Affirmed*by unpublished per curiam opinion.
#### Thomas Keithan *v.*Massachusetts Bonding and Insurance Company et al.

*Frank M. Grazioso,*for the appellee-appellant (plaintiff).

Argued October 7

decided October 7, 1969

The motion by Frank M. Grazioso to withdraw his appearance for the plaintiff in the appeal from the Superior Court in New Haven County is granted.
§ 58.43 Animal care facilities. ( a ) A testing facility shall have a sufficient number of animal rooms or areas, as needed, to assure proper: ( 1 ) Separation of species or test systems,
( 2 ) isolation of individual projects,
( 3 ) quarantine of animals, and
( 4 ) routine or specialized housing of animals.
( b ) A testing facility shall have a number of animal rooms or areas separate from those described in paragraph (a) of this section to ensure isolation of studies being done with test systems or test and control articles known to be biohazardous, including volatile substances, aerosols, radioactive materials, and infectious agents.
( c ) Separate areas shall be provided, as appropriate, for the diagnosis, treatment, and control of laboratory animal diseases. These areas shall provide effective isolation for the housing of animals either known or suspected of being diseased, or of being carriers of disease, from other animals.
( d ) When animals are housed, facilities shall exist for the collection and disposal of all animal waste and refuse or for safe sanitary storage of waste before removal from the testing facility. Disposal facilities shall be so provided and operated as to minimize vermin infestation, odors, disease hazards, and environmental contamination.
[43 FR 60013, Dec. 22, 1978, as amended at 52 FR 33780, Sept. 4, 1987]
§ 582.1431 Magnesium oxide. ( a ) *Product.* Magnesium oxide.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
[No. 20456-8-II.

Division Two.

December 12, 1997.]

#### The State of Washington, *Respondent,*v. Robert Chong Wiggins, *Appellant.*

Appeal from a judgment of the Superior Court for Thurston County, No. 95-1-01612-3, Richard D. Hicks, J., entered March 5, 1996. *Affirmed*by unpublished opinion per Hunt, J., concurred in by Houghton, C.J., and Bridge-water, J.